Breast cancer resistance protein in acute myeloid leukemia: Clini | 19876
Journal of Hematology & Thromboembolic Diseases

Journal of Hematology & Thromboembolic Diseases
Open Access

ISSN: 2329-8790

Breast cancer resistance protein in acute myeloid leukemia: Clinical relevance and prognostic significance

Joint Event on 12th International Conference on Hematology and Hematological Oncology & 6th International Conference on HIV/AIDS, STDs and STIs

October 29-30, 2018 | San Francisco, USA

Heba Gouda

Cairo University, School of Medicine, Egypt

Scientific Tracks Abstracts: J Hematol Thrombo Dis

Abstract :

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal disorder characterized by the accumulation of acquired genetic alterations in hematopoietic progenitor cells. The multidrug transporter Breast Cancer Resistance Protein (BCRP) gene expression is an important prognostic marker in adult AML. In this study, we measured BCRP mRNA expression by quantitative real-time RT-PCR in 100 de novo cytogenetically normal adult AML patients and 50 healthy normal controls. The expression was evaluated in relation to other clinical and prognostic factors as well as response to treatment and diseasefree survival. There was a positive correlation between BCRP gene over-expression and the percent of CD34 expression. This coexpression was associated with a lower complete response (CR) rate and with worse event-free survival and overall survival. We conclude that co-expression of CD34 and BCRP reflects a clinically resistant subgroup of adult AML.

Biography :

Heba Gouda has completed her MD degree since 2005 she has more than 26 international publication in the field of hematology and stem cell research, she is a full professor of clinical and chemical pathology since 2010 at the school of medicine Cairo University (ranked among the first 250 medical schools all over the world). She has a professional health care and hospital management diploma from the American University in Cairo since 2017.